title: Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis.
abstract: We herein report the case of a 57-year-old woman presenting with a biopsy-proven tumefactive demyelinating lesion as her first clinical event. Subsequently, she displayed a relapsing-remitting course with recurrence of large demyelinating lesions exceeding 2 cm in diameter rather than the small ovoid lesions characteristic of multiple sclerosis. Administration of interferon beta did not suppress the disease activity. Finally, treatment with natalizumab, which is a humanized monoclonal antibody against the cell-adhesion molecule α4-integrin, was initiated, resulting in clinical and radiological stabilization. Our experience here suggests that natalizumab may be an effective therapeutic option for relapsing-remitting tumefactive multiple sclerosis with high disease activity.
authors.affiliation: Department of Neurology, Kansai Medical University, Japan.
authors.forename: Masataka
authors.initials: M
authors.lastname: Nakamura
authors.forename: Kumi
authors.initials: K
authors.lastname: Itani
authors.forename: Kousuke
authors.initials: K
authors.lastname: Miyake
authors.forename: Takenobu
authors.initials: T
authors.lastname: Kunieda
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kaneko
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Kusaka
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D039441:Integrin alpha4 / Q000276:immunology; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy; D000069442:Natalizumab / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D039441:Integrin alpha4